Our Pipeline

Our Pipeline consist of three group of products, with multiple potential candidates:

  • NewroBus: Nano-size, single-chain antibodies carrying biologics through the Blood-Brain Barrier (BBB)
  • TNF-α Inhibitors: potent, TNF-α inhibitors nano antibodies (TNFI)
  • Alzheimer’s Disease Candidate: Hetero-trimer molecules consisting of one NewroBus molecule linked to two molecule of TNF-α inhibitors

NewroBus

Nano-size, single-chain antibodies that can carry biologics through the Blood-Brain Barrier. Four compounds have been selected from a large pool of potential candidates based on their ability to cross BBB without interfering with Tf binding and uptake, and also based on humanness, specificity, BBB permeability and tolerability. NewroBus compound are versatile and can be used to carry different biologics across the BBB.

NN-101

Discovery
In-Vivo
Pre-IND
IND
Web Designer
Phase 1
Web Designer

NN-102

NN-103

NN-104

NewroBus Pipeline

TNF-α inhibitors

Two potent, TNF-α inhibitors nano-antibodies (TNFI) have been developed to be used in conjunction with NewroBus technology to treat Alzheimer’s disease and other neurodegenerative diseases where TNF-α plays a pathogenic role. These TNFI do not cross the BBB by themselves.

NN-223

Discovery
In-Vivo
Pre-IND
IND
Phase 1

NN-224

tnf-alpha pipeline

Alzheimer’s Disease Candidate

Our lead product for the treatment of Alzheimer’s Disease is NN-841, a hetero-trimer consisting of one molecule of NewroBus NN-103 linked to two molecules of TNF-α inhibitors NN-224.

Lead Compound

NN-841

Discovery
In-Vivo
Pre-IND
IND
Phase 1
lead compound pipeline
Scroll to Top